

Factor Xa inhibitors - Pipeline Insight, 2022

<https://marketpublishers.com/r/F960F73F2BB5EN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: F960F73F2BB5EN

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Factor Xa inhibitors - Pipeline Insight, 2022" report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Factor Xa inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Factor Xa inhibitors Understanding

Factor Xa inhibitors: Overview

Inhibition of clotting factor Xa has been evaluated as a potential target for anticoagulation therapy with the hypothesis that using target-specific therapy will alleviate some of the dosing variability observed with the vitamin K antagonist. The FXa inhibitors have a unique mechanism of action compared with the VKA historically used for oral anticoagulation. FXa is common to both the intrinsic and extrinsic pathways of the clotting cascade making it an excellent target for anticoagulation therapy. It plays a significant role in the formation of thrombin from prothrombin. A single molecule of Xa leads to the creation of 1000 molecules of thrombin. Inhibition of Xa leads to a significant reduction in thrombin and ultimately clot formation

All of the currently available FXa inhibitors are contraindicated for use in patients experiencing active bleeding. In addition, they all carry United States (US) Black Boxed Warnings for premature discontinuation and spinal/epidural hematomas. The risk for ischemic events increases when FXa inhibitors are discontinued without an adequate alternative oral or parenteral anticoagulant in place. There is also a risk for the development of spinal/epidural hematomas when FXa inhibitors are used in patients undergoing spinal procedures including neuroaxial anesthesia and spinal puncture.

Currently available FXa inhibitors have been shown to be noninferior to warfarin with regards to efficacy and safety in clinical trials and are viable treatment options for patients with nonvalvular atrial fibrillation.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Factor Xa inhibitors R&D. The therapies under development are focused on novel approaches for Factor Xa inhibitors.

Factor Xa inhibitors Emerging Drugs Chapters

This segment of the Factor Xa inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Factor Xa inhibitors Emerging Drugs

Rivaroxaban: Bayer

Rivaroxaban acts as inhibitor of Factor Xa. It is approved for Stroke, Embolism, VenousThromboembolism, Deep vein thrombosis. It is currently in phase III for Arterial thrombosis, Peripheral arterial disorders, Venous thrombosis and is being developed by Bayer.

Further product details are provided in the report.....

Factor Xa inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Factor Xa inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Factor Xa inhibitors

There are approx. 6+ key companies which are developing the Factor Xa inhibitors. The companies which have their Factor Xa inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Bayer.

Phases

DelveInsight's report covers around 6+ products under different phases of clinical development like

Late-stage products (Phase III)

Mid-stage products (Phase II)

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Factor Xa inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Factor Xa inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Factor Xa inhibitors therapeutic drugs

key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Factor Xa inhibitors drugs.

Factor Xa inhibitors Report Insights

Factor Xa inhibitors Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Factor Xa inhibitors Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing Factor Xa inhibitors drugs?

How many Factor Xa inhibitors drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for Factor Xa inhibitors?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Factor Xa inhibitors therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Factor Xa inhibitors and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Chong Kun Dang Pharmaceutical

Carbomimetics

CSPC ZhongQi Pharmaceutical Technology

Bayer

AMAG Pharmaceuticals

Pfizer

Key Products

CKD-344

CM20201

SYHA-136

Rivaroxaban

Ciraparantag

PF-05230907

Contents

Introduction

Executive Summary

Factor Xa inhibitors: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Factor Xa inhibitors– DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Factor Xa inhibitors companies' collaborations, Licensing, Acquisition -Deal Value

Trends

Factor Xa inhibitors Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Rivaroxaban: Bayer

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

Drug Name: Company Name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

CKD-344: Chong Kun Dang Pharmaceutical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.....
Preclinical and Discovery Stage Products
Comparative Analysis
CM20201: Carbomimetics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.....
Inactive Products
Comparative Analysis
Factor Xa inhibitors Key Companies
Factor Xa inhibitors Key Products
Factor Xa inhibitors- Unmet Needs
Factor Xa inhibitors- Market Drivers and Barriers
Factor Xa inhibitors- Future Perspectives and Conclusion
Factor Xa inhibitors Analyst Views
Factor Xa inhibitors Key Companies
Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Factor Xa inhibitors

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Factor Xa inhibitors
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Factor Xa inhibitors - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/F960F73F2BB5EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/F960F73F2BB5EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970